N4 Pharma losses widen as it works on commercialising Nuvec
24th Feb 2021 12:34
(Sharecast News) - Pre-revenue specialist pharmaceuticals company N4 Pharma reported an operating loss of £1.56m in its final results on Wednesday, widening from the £0.95m loss a year earlier.
Read moreN4 Pharma shares surge on latest from Nanomerics collaboration
3rd Dec 2020 13:39
(Sharecast News) - Specialist pharmaceuticals company N4 Pharma updated the market on its ongoing research collaboration agreement with Nanomerics on Thursday.
Read moreN4 Pharma working with Nanomerics on oncology programme
9th Nov 2020 14:22
(Sharecast News) - Specialist pharmaceutical company N4 Pharma has appointed Nanomerics to investigate the potential utility of its 'Nuvec' delivery system in cancer therapy.
Read moreN4 Pharma plunges as Covid-19 progress stalls
14th Sep 2020 09:04
(Sharecast News) - N4 Pharma lost more than a third of its value after the company said its potential Covid-19 vaccine delivery method did not produce a positive result at stage 3 of tests.
Read moreN4 Pharma chooses Ardena as contract manufacturing partner
1st Sep 2020 09:19
(Sharecast News) - Specialist pharmaceutical company N4 Pharma has appointed the API and nanomedicines business unit of Ardena as its contract development and manufacturing organisation partner for the technology transfer and upscaling manufacture of 'Nuvec', it announced on Tuesday.
Read moreN4 Pharma completes first stage proof of concept work for Nuvec
28th May 2020 09:47
(Sharecast News) - Pharmaceutical group N4 Pharma has completed the first phase of Covid-19 proof of concept work for Nuvec, the group's novel delivery system for cancer treatments and vaccines.
Read moreN4 Pharma raises ?2.03m via oversubscribed placing
13th May 2020 11:30
(Sharecast News) - Specialist pharmaceutical company N4 Pharma has raised ?2.03m through an oversubscribed placing of 50,731,250 new ordinary shares, it announced on Wednesday, at a price of 4p each.
Read moreN4 Pharma files for new UK patent on 'Nuvec'
24th Apr 2020 09:30
(Sharecast News) - Specialist pharmaceutical company N4 Pharma has filed a new UK patent application around both the ability of its 'Nuvec' delivery system ability to be used to manufacture viral vectors, and to make viral vectors more efficient in applications such as ex-vivo gene therapy treatments.
Read moreN4 Pharma narrows loss as it continues development work
25th Feb 2020 08:49
(Sharecast News) - Specialist pharmaceutical company N4 Pharma reported a smaller operating loss for 2019 on Tuesday, at ?0.95m, compared to ?1.42m in the prior year.
Read moreN4 Pharma shares rise on partnership with Nanomerics
11th Feb 2020 14:19
(Sharecast News) - Specialist pharmaceutical company N4 Pharma has signed a 14-month research collaboration with Nanomerics to produce and test two candidate formulations using its 'Nuvec' delivery system, it announced on Tuesday.
Read moreN4 Pharma reassures shareholders over future of 'Nuvec'
15th Apr 2019 15:33
(Sharecast News) - Specialist pharmaceutical company N4 Pharma updated the market on the development of 'Nuvec' on Monday, following the disclosure of inconsistencies in the efficacy of Nuvec between various in vitro and in vivo studies.
Read moreN4 Pharma raises £1.05m in placing to advance vaccine delivery system
8th Feb 2019 12:00
(Sharecast News) - Specialist pharmaceutical company N4 Pharma said on Friday that it has raised £1.05m before expenses in a placing of 10.5m new ordinary shares to fund its vaccine delivery system.
Read moreN4 Pharma extends 'Nuvec' licence agreement with Aussie university firm
20th Dec 2018 15:06
(Sharecast News) - Specialist pharmaceutical company N4 Pharma has extended the terms of its licence agreement with UniQuest - a University of Queensland company - for the exploitation of its novel delivery system 'Nuvec' on Thursday.
Read moreN4 Pharma bears more good news on its Nuvec particles
28th Nov 2018 11:30
(Sharecast News) - Specialist pharmaceutical company N4 Pharma updated on the latest key research findings for its 'Nuvec' delivery system on Wednesday.
Read moreN4 Pharma pleased with latest test results on 'Nuvec'
29th Oct 2018 11:32
(Sharecast News) - Specialist pharmaceutical company N4 Pharma updated the market on the latest key research findings for its 'Nuvec' delivery system on Monday, reporting that the Nuvec particles had a "clear adjuvant effect" to help deliver a level of immune response for both the mRNA and pDNA OVA antigens, comparable to that of existing delivery systems.
Read more